

## **Clinical Policy: Febuxostat (Uloric)**

Reference Number: CP.PMN.57

Effective Date: 08.01.13

Last Review Date: 02.23

Line of Business: HIM, Medicaid

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

### **Description**

Febuxostat (Uloric<sup>®</sup>) is a xanthine oxidase inhibitor.

### **FDA Approved Indication(s)**

Uloric is indicated for the chronic management of hyperuricemia in patients with gout who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable.

Limitation(s) of use: Uloric is not recommended for the treatment of asymptomatic hyperuricemia.

### **Policy/Criteria**

*Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.*

It is the policy of health plans affiliated with Centene Corporation<sup>®</sup> that Uloric is **medically necessary** when the following criteria are met:

#### **I. Initial Approval Criteria**

##### **A. Hyperuricemia (must meet all):**

1. Diagnosis of hyperuricemia associated with gout;
2. Current (within the last 30 days) serum urate  $\geq 6$  mg/dL;
3. Age  $\geq 18$  years;
4. One of the following (a or b):
  - a. Failure of combination urate-lowering therapy (allopurinol and probenecid **OR** allopurinol and probenecid-containing product) at up to maximally tolerated doses;
  - b. Member has intolerance or contraindication to combination urate-lowering therapy, and failure of allopurinol or probenecid, at up to maximally tolerated doses, unless clinically significant adverse effects are experienced or both are contraindicated;
5. Uloric is not prescribed concurrently with azathioprine or mercaptopurine;
6. Dose does not exceed both of the following (a and b):
  - a. 80 mg per day;
  - b. 1 tablet per day.

##### **Approval duration:**

**HIM** – 12 months

**Medicaid** – Length of Benefit

**B. Other diagnoses/indications** (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
  - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: HIM.PA.33 for health insurance marketplace and CP.PMN.255 for Medicaid; or
  - b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: HIM.PA.103 for health insurance marketplace and CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: HIM.PA.154 for health insurance marketplace and CP.PMN.53 for Medicaid.

**II. Continued Therapy**

**A. Hyperuricemia** (must meet all):

1. Member meets one of the following (a or b):
  - a. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
  - b. Member is currently receiving medication and is enrolled in a state and product with continuity of care regulations (*refer to state specific addendums for CC.PHARM.03A and CC.PHARM.03B*);
2. Member is responding positively to therapy as evidenced by, including but not limited to, improvement in any of the following parameters:
  - a. Reduced frequency of gout attacks;
  - b. Serum urate level < 6 mg/dL;
3. If request is for a dose increase, new dose does not exceed both of the following (a and b):
  - a. 80 mg per day;
  - b. 1 tablet per day.

**Approval duration:**

**HIM** – 12 months

**Medicaid** – Length of Benefit

**B. Other diagnoses/indications** (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
  - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: HIM.PA.33 for health insurance marketplace and CP.PMN.255 for Medicaid; or

- b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: HIM.PA.103 for health insurance marketplace and CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: HIM.PA.154 for health insurance marketplace and CP.PMN.53 for Medicaid

**III. Diagnoses/Indications for which coverage is NOT authorized:**

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – HIM.PA.154 for health insurance marketplace and CP.PMN.53 for Medicaid or evidence of coverage documents.

**IV. Appendices/General Information**

*Appendix A: Abbreviation/Acronym Key*

FDA: Food and Drug Administration

*Appendix B: Therapeutic Alternatives*

*This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.*

<b>Drug Name</b>	<b>Dosing Regimen</b>	<b>Dose Limit/ Maximum Dose</b>
allopurinol (Zyloprim®)	100 mg PO QD; may be increased by 100 mg every 2 to 4 weeks until serum urate concentration is ≤ 6 mg/dL or until maximum of 800 mg/day is reached	800 mg/day
probenecid	250 mg PO BID for the first week, then 500 mg PO BID	2 g/day
colchicine (Colcrys®, Mitigare®)	Prevention of gout flares: 0.6 mg PO QD or BID	Prevention of gout flares: 1.2 mg/day
probenecid/colchicine	1 tablet (probenecid 500 mg/colchicine 0.5 mg) PO QD for 1 week, then 2 tablet PO BID	4 tablets/day of probenecid/colchicine (each tablet with 500 mg of probenecid/0.5 mg colchicine) is the usual maximally tolerated dose

*Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.*

*Appendix C: Contraindications/Boxed Warnings*

- Contraindication(s): patients being treated with azathioprine or mercaptopurine

- Boxed warning(s): none reported

*Appendix D: General Information*

- In November 2017, the FDA MedWatch issued an alert to the public regarding the preliminary results from a safety clinical trial that showed an increased risk of heart-related death with febuxostat compared to allopurinol. The febuxostat drug labels already carried a Warning and Precaution about cardiovascular events because the clinical trials conducted before approval showed a higher rate of heart-related problems in patients treated with febuxostat compared to allopurinol. These problems included heart attacks, strokes, and heart-related deaths. As a result, the FDA required an additional safety clinical trial after the drug was approved and on the market to better understand these differences, and that trial result continued to show increased heart-related death with febuxostat.
- Per 2020 ACR guidelines, the minimum threshold for all patients on urate-lowering therapy is < 6.8 mg/dL. For patients with non-palpable, non-tophaceous disease in long-term clinical remission (for several years) and whose serum urate level is < 6.8 mg/dL, there is not a need for drug therapy to be up titrated for the sole purpose of reaching a goal of serum urate < 6 mg/dL. However, for all other patients with gout and recent symptoms of gout or tophi, the recommended target goal is a serum urate level < 6 mg/dL.

**V. Dosage and Administration**

Indication	Dosing Regimen	Maximum Dose
Hyperuricemia in patients with gout	40 mg or 80 mg PO QD	80 mg/day

**VI. Product Availability**

Tablets: 40 mg, 80 mg

**VII. References**

1. Uloric Prescribing Information. Deerfield, IL: Takeda Pharmaceuticals America, Inc; February 2019. Available at: [www.uloiric.com](http://www.uloiric.com). Accessed September 30, 2022.
2. Khanna D, Fitzgerald JD, Khanna PJ, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. *Arthritis Care Res* 2012; 64(10): 1431-1446.
3. FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. *Arthritis Care & Research*. June 2020; 0 (0): 1-17.
4. Richette P, Doherty M, Pascual E, et al. 2016 Updated EULAR evidence-based recommendations for the treatment of gout. *Ann Rheum Dis* 2016; 0:1–14. Doi:10.1136/annrheumdis-2016-209707.
5. Qaseem A, Harris RP, Forciea MA, et al. Management of acute and recurrent gout: A clinical practice guideline from the American College of Physicians. *Ann Intern Med*. 2017; 166(1): 58-68.
6. Fitzgerald JD, Mikuls TR, Neogi T, et al. Development of the American College of Rheumatology electronic clinical quality measures for gout. *Arthritis Care & Research*. 2018;70(5):659-671. Doi: 10.1002/acr.23500.

7. Fitzgerald JD, Terkeltaub R, Khanna D, Khanna P. July 2018 author statement explaining different serum urate targets in 2012 ACR gout guideline and 2018 ACR electronic clinical quality measures for gout. American College of Rheumatology. Available at: <https://www.rheumatology.org/Portals/0/Files/ACR-Gout-Guideline-Author-Statement.pdf>.

Reviews, Revisions, and Approvals	Date	P&T Approval Date
1Q 2019 annual review: removed requirement for trial within the last 6 months; modified max dose requirement to max dose tolerated; no significant changes from previously approved corporate policy; references reviewed and updated.	10.30.18	02.19
No significant changes: added updated FDA indication: Uloric is indicated for use after inadequate response, intolerance, or unable to take allopurinol; references reviewed and updated.	03.08.19	
No significant changes: clarified combination urate-lowering therapy requirement to require monotherapy if member is unable to use combination regimen.	05.02.19	
1Q 2020 annual review: no significant changes; updated verbiage for tiered redirection; references reviewed and updated.	10.28.19	02.20
1Q 2021 annual review: no significant changes; added examples of positive response included in Appendix D to section II; references to HIM.PHAR.21 revised to HIM.PA.154; references reviewed and updated.	11.16.20	02.21
1Q 2022 annual review: no significant changes; references reviewed and updated	11.20.21	02.22
Clarified requirement for trial of probenecid/colchicine as “probenecid-containing product”	04.06.22	
Template changes applied to other diagnoses/indications and continued therapy section.	10.07.22	
1Q 2023 annual review: no significant changes; updated dosing in Appendix B; updated template language for continued therapy and other diagnoses/indication sections; references reviewed and updated.	09.30.22	02.23

**Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

**Note:**

**For Medicaid members**, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2013 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or

remove any trademark, copyright or other notice contained herein. Centene<sup>®</sup> and Centene Corporation<sup>®</sup> are registered trademarks exclusively owned by Centene Corporation.